CGTX

CGTX

USD

Cognition Therapeutics Inc. Common Stock

$1.570-0.030 (-1.875%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$1.600

最高

$1.630

最低

$1.550

交易量

1.39M

公司基本面

市值

138.5M

行業

生物科技

國家

United States

交易統計

平均交易量

5.54M

交易所

NCM

貨幣

USD

52週範圍

最低 $0.222當前 $1.570最高 $3.83

相關新聞

GlobeNewswire

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced

查看更多
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target
GlobeNewswire

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed

查看更多
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
GlobeNewswire

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders -

查看更多
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
GlobeNewswire

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was

查看更多
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement